The Basque biotech company ONCOMATRYX BIOPHARMA, S.A. has successfully completed a capital increase of approximately €58 million, with the ultimate goal of evolving from a biotech company to an integrated biopharmaceutical company, strengthening both its clinical development and industrial capabilities.
The operation is supported by the Ministry of Science, Innovation and Universities through the public venture capital company Innvierte, as well as by Kutxa Fundazioa, the Basque Government, Ekarpen, BBK, and other historical private investors, both national and international.
Strategic initiatives include the development of a Fill & Finish manufacturing plant in Gipuzkoa, specialized in high-potency oncology drugs. This infrastructure will help reinforce Europe’s industrial capacity in the production of advanced biological medicines and strengthen the technological autonomy of the pharmaceutical sector.
The Ministry of Science, Innovation and Universities, through the public venture capital company INNVIERTE of CDTI, the State Innovation Agency, will contribute €24.3 million from its co-investment line for strategic companies. This operation is part of the Spanish Government’s commitment to specifically promote technological innovation in healthcare, generating value and improving citizens’ quality of life.
Kutxa Fundazioa will allocate €15 million of the total €58 million round launched by Oncomatryx, significantly increasing its stake in the company from 1.7% to 7.4%. With this decision, the foundation reaffirms its strategic mission to contribute to social welfare by promoting business development and industrial impact in Gipuzkoa.
“This investment fully aligns with our objectives of fostering innovation and competitiveness, consolidating our commitment to transformative projects that generate real impact in our ecosystem,” said Eluska Sukia, Investment Director at Kutxa Fundazioa.
The Basque Government, in collaboration with Ekarpen, will contribute €10.4 million in this new funding round, which, according to Mikel Jauregi, Minister of Industry, Energy Transition and Sustainability, “will maintain our 17.96% shareholding in the company. Through this operation, we reinforce our commitment to developing a highly specialized biotech sector, considered strategic for the competitiveness and diversification of the Basque industrial landscape.”
He added, “This investment helps consolidate Gipuzkoa as a hub for innovation in life sciences and advanced technologies, promoting high-value scientific and technological capabilities and creating qualified jobs for which our children aspire.”
The Minister of Science, Innovation and Universities, Diana Morant, stated: “This operation is an example of the public-private collaboration model promoted by the Spanish Government to strengthen our science and innovation system. Supporting Oncomatryx means supporting more advanced oncology therapies, industrial capacity in biomedicine, and positioning Spain at the forefront of biotechnology for health and citizens’ quality of life.”
Scientific, economic, and social impact
For Laureano Simón, founder of Oncomatryx: “This capital increase is much more than a financial operation. It confirms that Oncomatryx is ready to take the leap from a research company to an integrated biopharmaceutical company. The support of institutional and private investors who have backed this project for years allows us to advance in building our own industrial infrastructure, strengthening Europe’s capacity to produce the oncology drugs of the future.”
Oncomatryx approaches cancer from a different perspective than traditional methods, targeting the tumor microenvironment, a key factor in tumor growth and resistance. This pioneering approach opens new therapeutic pathways to improve treatment efficacy.
Its drug OMTX705 is currently in Phase 1B-2A clinical trials with patients, following a first phase in which 100 patients were treated at leading hospitals in Spain and the United States, with promising results and high expectations in both clinical and scientific communities.
Oncomatryx holds international licensing agreements with Asian biotech companies, validating its technology platform globally, and has been recognized by the European Union as a strategic project through the EIC Accelerator program, which has supported its development with €12.5 million.
This scientific positioning places Oncomatryx in a unique position within the development of new oncology therapies.
The investment will also position Euskadi as a key hub for advanced oncology therapies, generating qualified employment and attracting high-value industrial activity.
cloud technology axon
Thanks to the support of CDTI Innovación, the Catalan company Abrasto...
